Talphera to Present at H.C. Wainwright Investment Conference

SAN MATEO, Calif., Sept. 3, 2026 /CourierPR/ -- Talphera, Inc., a specialty pharmaceutical company, is set to participate in the H.C. Wainwright 28th Annual Global Investment Conference, presenting its latest developments and strategies to investors and industry experts.

On Monday, September 14, 2026, at 4:30 PM Eastern Time, Chief Executive Officer Vince Angotti and Chief Medical Officer Shakil Aslam, MD, will present at the conference held in New York City. The session will feature a fireside chat followed by one-on-one meetings, providing attendees with an opportunity to engage directly with Talphera’s management team.

Talphera’s presentation will focus on its lead product candidate, Niyad®, a lyophilized formulation of nafamostat. Currently under investigation as an anticoagulant for the extracorporeal circuit, Niyad® has been granted Breakthrough Device Designation status by the U.S. Food and Drug Administration (FDA). The company will also share updates on its ongoing clinical trials and future plans for commercialization.

The conference will be accessible via webcast, which can be viewed through Talphera’s website under the News & Events section of the Investors page. A replay of the event will be available for 90 days following the conference.